NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at implementing and supporting two brand-new patient registries on its proprietary NORD® IAMRARE® platform. This significant initiative is made possible through critical funding provided by the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®), a collaborative agreement established with the Critical Path Institute and funded by the U.S. Food and Drug Administration (FDA).
The announcement marks another major step forward in the ongoing effort to empower rare disease patient communities, giving them the necessary infrastructure, technology, and professional guidance required to collect standardized, high-quality patient-reported data. By leveraging the established IAMRARE platform, the selected rare disease organizations will be positioned to accelerate research and contribute valuable insights to the broader medical and regulatory communities.
Reflecting on the importance of community-led research, Tracey Sikora, Vice President of Research and Clinical Programs at NORD, emphasized the profound impact that these registries can achieve over time.
"This opportunity builds on NORD’s work supporting rare disease nonprofits. Research studies led by rare disease communities are an important source of data, and insights from IAMRARE-hosted studies have contributed to the development of clinical outcome assessments, updates to treatment guidelines, and at least one FDA approval," says Tracey Sikora, Vice President of Research and Clinical Programs at NORD.
Under the terms of this latest funding opportunity, successful applicants will collaborate closely with NORD beginning in April 2027 to build, launch, and maintain a specialized patient registry tailored specifically to their unique rare disease community. Throughout the implementation process and beyond, NORD will take on the responsibility of building and hosting the dedicated registry website. Furthermore, NORD will provide comprehensive training and ongoing support to the registry sponsors as they navigate the multifaceted operational landscape of clinical research.
This comprehensive support system covers a wide array of foundational tasks, including establishing a dedicated registry advisory board, developing a rigorous study protocol, building and customizing patient surveys, navigating the complex Institutional Review Board (IRB) process, and determining transparent criteria and governance policies for sharing the collected data with qualified external researchers. By handling the heavy technical lifting and administrative guidance, NORD ensures that smaller patient advocacy organizations can successfully spearhead research initiatives without needing extensive prior technical infrastructure.
Organizations interested in seizing this unique opportunity must ensure they meet the specific application criteria outlined by NORD. The application window is officially open, and eligible groups have until January 10, 2027, to submit their completed application packages. Following the review period, accepted applicants will be formally notified by February 1, 2027, paving the way for official registry implementation to kick off in April 2027.
Prospective applicants can access the application portal online, while any inquiries regarding the request for applications process can be directed to NORD’s designated communications channel.
About the NORD® IAMRARE® Platform
The NORD® IAMRARE Platform serves as a robust, specialized technological ecosystem designed specifically to empower patient advocacy organizations to collect structured, patient-reported data securely and efficiently. To date, the platform proudly hosts more than 55 live registries sponsored by various patient advocacy organizations, all working toward the common goal of advancing scientific understanding and therapeutic development for their respective conditions. Additional information regarding the platform and its capabilities can be found by visitingiamrare.org.
About the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®)
The Rare Disease Cures Accelerator–Data and Analytics Platform is an innovative, FDA-sponsored initiative engineered to provide a centralized, standardized infrastructure. Its core mission is to support and dramatically accelerate rare disease characterization, thereby streamlining and expediting the overall process of medical therapy development. Further details about the platform and its ongoing collaborative projects are available through the Critical Path Institute at c-path.org/programs/rdca-dap.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) stands as a prominent, independent, and nonpartisan nonprofit organization passionately dedicated to improving the health, well-being, and overall lives of the more than 30 million Americans currently affected by rare diseases.
NORD operates through expansive partnerships with more than 350 disease-specific member patient organizations. In addition, its network encompasses 49 designated NORD Rare Disease Centers of Excellence spanning over 170 academic medical centers, specialized research institutions, and children’s hospitals situated nationwide. Through these collaborative networks, NORD continuously advances high-quality care, vital research initiatives, educational programming, and legislative advocacy to forge a brighter, more promising future for every individual and family impacted by a rare disease. Comprehensive information and resources can be accessed directly at rarediseases.org.
Media Contact:
Cheryl Herbert
Vice President, Marketing & Communications
National Organization for Rare Disorders (NORD®)
